Literature DB >> 25353970

Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.

Hideki Terai1, Kenzo Soejima1, Hiroyuki Yasuda1, Takashi Sato1, Katsuhiko Naoki2, Shinnosuke Ikemura1, Daisuke Arai1, Keiko Ohgino1, Kota Ishioka1, Junko Hamamoto1, Yae Kanai3, Tomoko Betsuyaku1.   

Abstract

This study was designed to identify epigenetically regulated genes and to clarify the contribution of epige-netic alteration to acquired resistance to epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs). We established a gefitinib‑resistant lung cancer cell line, PC9, which was originally gefitinib‑sensitive, by serial long‑term exposure to gefitinib. RNA and DNA were collected from both gefitinib‑sensitive and ‑resistant PC9 cells, and comprehensive DNA methylation and mRNA expression analyses were performed using Infinium HumanMethylation27 Bead Arrays and Agilent SurePrint G3 Human Gene Expression 8x60K Array, respectively. DNA methylation was increased in 640 genes in gefitinib‑resistant cells compared to parental cells. Among them, we selected 29 candidate genes that presented a decrease in mRNA expression in resistant PC9. We further studied four of the selected genes (C10orf116, IGFBP3, KL, and S100P) and found that KL or S100P silencing by siRNA induced a decrease in gefitinib sensitivity compared to that in the negative control in PC9. In conclusion, KL and S100P could be potential targets to overcome resistance to EGFR‑TKIs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25353970     DOI: 10.3892/ijo.2014.2733

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

Review 1.  Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.

Authors:  Lu Huang; Zhi Liao; Zhixi Liu; Yan Chen; Tingwenli Huang; Hongtao Xiao
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

Review 2.  Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Authors:  Herbert H Loong; Sui-Chun Sampson Kwan; Tony Shu-Kam Mok; Yat-Ming Lau
Journal:  Curr Treat Options Oncol       Date:  2018-09-29

3.  Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Tae-Gul Lee; Eun-Hui Jeong; Il Jae Min; Seo Yun Kim; Hye-Ryoun Kim; Cheol Hyeon Kim
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

4.  Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA.

Authors:  Kiyoshi Misawa; Atsushi Imai; Hirotaka Matsui; Akinori Kanai; Yuki Misawa; Daiki Mochizuki; Masato Mima; Satoshi Yamada; Tomoya Kurokawa; Takuya Nakagawa; Hiroyuki Mineta
Journal:  Oncogene       Date:  2020-05-15       Impact factor: 9.867

Review 5.  [Research Progress of Epigenetic Mechanism in Acquired Resistance of 
Targeted Therapy in Non-small Cell Lung Cancer].

Authors:  Xin Ai; Yan Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.